UroGen Pharma URGN Cash Flow Statement
| TTM Q1 '26 | TTM Q4 '25 | TTM Q3 '25 | TTM Q2 '25 | TTM Q1 '25 | ||
|---|---|---|---|---|---|---|
| -$133.23M+13.2% | -$153.49M+6.8% | -$164.64M-6.2% | -$154.97M-11.9% | -$138.43M-9.1% | ||
| $350K+0.9% | $347K+2.1% | $340K0.0% | $340K0.0% | $340K-13.0% | ||
| $13.52M+13.0% | $11.96M-1.4% | $12.13M-3.7% | $12.59M-6.2% | $13.42M+2.4% | ||
| —— | —— | —— | —— | —— | ||
| $13.33M+84.2% | $7.24M+869% | $747K+338% | -$314K-190% | $347K-90.2% | ||
| $5.02M+1,657% | $286K-95.6% | $6.49M— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| -$685K-239% | -$202K-20,100% | -$1K-100% | $262K-61.6% | $683K+242% | ||
| $2.26M+7.2% | $2.1M+21.1% | $1.74M+26.2% | $1.38M+30.6% | $1.05M+23.0% | ||
| —— | —— | -$2.38M-22.9% | -$1.94M-27.0% | -$1.53M-47.5% | ||
| —— | —— | —— | —— | —— | ||
| -$165.74M-2.0% | -$162.44M-17.9% | -$137.74M-11.9% | -$123.13M-15.0% | -$107.06M-10.6% | ||
| $299K+3.5% | $289K-25.3% | $387K-2.3% | $396K+16.8% | $339K+14.9% | ||
| $102.96M-26.1% | $139.25M-23.0% | $180.94M+18.4% | $152.87M+13.6% | $134.62M+25.0% | ||
| $66.83M+8.6% | $61.56M— | —— | —— | —— | ||
| —— | —— | —— | —— | $18.37M-25.0% | ||
| $39.8M0.0% | $39.8M+399% | $7.97M-46.9% | $15M-84.5% | $96.52M-36.2% | ||
| —— | $1.86M+33.3% | $1.39M+50.0% | $927.5K+100% | $463.75K— | ||
| $105.09M+163% | $39.92M+360% | $8.67M-78.3% | $40.01M-71.4% | $140M-28.1% | ||
| —— | —— | -$34.6M— | —— | —— | ||
| $1.08M-42.7% | $1.88M-40.2% | $3.14M-22.6% | $4.05M+16.3% | $3.48M+20.4% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$2.38M-22.9% | -$1.94M-27.0% | -$1.53M-47.5% | ||
| -$685K-239% | -$202K-20,100% | -$1K-100% | $262K-61.6% | $683K+242% | ||
| —— | —— | —— | —— | $2.49M+274% | ||
| $2.26M+7.2% | $2.1M+21.1% | $1.74M+26.2% | $1.38M+30.6% | $1.05M+23.0% | ||
| $102.96M-26.1% | $139.25M-23.0% | $180.94M+18.4% | $152.87M+13.6% | $134.62M+25.0% | ||
| —— | $1.86M+33.3% | $1.39M+50.0% | $927.5K+100% | $463.75K— | ||
| $5.81M+103% | $2.87M-62.6% | $7.66M-17.3% | $9.26M-12.5% | $10.59M-29.8% | ||
| —— | —— | —— | —— | —— | ||
| —— | —— | -$2.38M-22.9% | -$1.94M-27.0% | -$1.53M-47.5% | ||
| —— | $112K-52.0% | $233.25K-34.2% | $354.5K-25.5% | $475.75K-20.3% | ||
| —— | —— | —— | —— | $3.13M— | ||
| $5.44M-26.7% | $7.43M-19.1% | $9.18M+61.6% | $5.68M+30.1% | $4.37M+88.1% | ||
| —— | —— | —— | —— | $3.13M— | ||
| -$166.04M-2.0% | -$162.73M-17.8% | -$138.13M-11.8% | -$123.53M-15.0% | -$107.39M-10.6% | ||
| -$166.04M-2.0% | -$162.73M-17.8% | -$138.13M-11.8% | -$123.53M-15.0% | -$107.39M-10.6% |
Chart any of these lines over time, or line them up against competitors.
Compare these in charts →Questions, answered.
- How much cash does UroGen Pharma generate?
- UroGen Pharma (URGN) generated -$165.7M in operating cash flow over the trailing twelve months.
- What is UroGen Pharma's free cash flow?
- After $299.0K of capital expenditures, UroGen Pharma's free cash flow was -$166.0M over the trailing twelve months, down 54.6% year over year.
- Where does UroGen Pharma's cash flow data come from?
- Every line is extracted from UroGen Pharma's SEC filings (10-K and 10-Q) and tagged in XBRL. Switch between quarterly, annual, and trailing-twelve-month views, or open any line for its full history and peer comparisons.
